Search

Displaying results 2111 - 2120 of 5419 in total
  1. Drug

    Bitolterol

    go.drugbank.com/drugs/DB00901
    ApprovedWithdrawn

    Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

  2. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

  3. Drug

    Melarsomine

    go.drugbank.com/drugs/DB11528
    ExperimentalVet approved

    It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection. … Melarsomine is a trypanocidal agent marketed by Merial under the trade name Immiticide.

  4. Drug

    Biapenem

    go.drugbank.com/drugs/DB13028
    Investigational

    It is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008]

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Lanthanum carbonate

    go.drugbank.com/drugs/DB06792
    Approved

    Lanthanum carbonate is a phosphate binder marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. … It is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and preventing its absorption in the intestine.[L50733]

  6. Drug

    N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)

    go.drugbank.com/drugs/DB11202
    Approved

    N-alkyl ethylbenzyl dimethyl ammonium (c12-c14) is a quaternary ammonium compound with surfactant properties. It is found in sanitizing solutions or soaps as an active ingredient due to its antimicrobial properties. Employed in a great v...

  7. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    of cytokine release syndrome (CRS), a serious condition associated with the use of immunotherapy. … [A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can lead to the development

  8. Drug

    SO-101

    go.drugbank.com/drugs/DB05345
    Experimental

    SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia.

  9. Drug

    Insulin glargine

    go.drugbank.com/drugs/DB00047
    ApprovedInvestigational

    Insulin glargine is also available as the biosimilar, or "follow-on" product, Basaglar in the US and as Abasaglar in the EU. … Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.

  10. Drug

    Aceclidine

    go.drugbank.com/drugs/DB13262
    Approved

    [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]